ClinicalTrials.gg
RecruitingNCT07387068Updated Sep 9, 2026

Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors

A Phase 1 interventional study of GEN1079 in Advanced Solid Tumors, sponsored by Genmab. Recruiting at 12 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Genmab · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
121
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this trial is to learn about the safety and effectiveness of the antibody GEN1079 in participants with certain types of cancer.

The trial has multiple parts. The first part of the trial tests different doses of GEN1079 to find out if it is safe and determine what are the best doses to use. The second and third parts continue to test the safety of and whether GEN1079 works in additional participants with specific cancer types and at doses chosen based on results from the previous parts of the trial.

For each participant, the trial will last approximately 33 to 67 weeks but this may vary for each person. This includes up to 21 days for screening prior to receiving trial treatment, approximately 6 to 12 weeks of treatment (the duration of treatment may vary for each participant), and approximately 24 to 52 weeks of follow up after trial treatment ends (the duration of follow up may vary for each participant). During the screening, tumor tissue either collected prior to this trial or freshly collected during screening will be provided by all participants.

Participation in the trial will require visits to the site, with more frequent visits at the start of treatment and then less frequent visits afterwards. At site visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity, computed tomography [CT] scans) to monitor whether the treatment is safe and effective.

All participants will receive active drug; no one will be given placebo.

Read the detailed description

This is a first-in-human (FIH), Phase 1, open-label, multinational, dose escalation and expansion trial in participants with advanced selected solid tumors.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Genmab is the lead sponsor of 72 studies on the registry; 15 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 13 (57%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

All Parts:

  • Must have confirmed selected solid cancers.
  • Have according to (RECIST) v1.1. The measurable lesion(s) must be outside the field of prior radiation therapy unless there is documented progression in the lesion(s).
  • Must provide formalin-fixed paraffin-embedded tumor tissue (aspirates and bone specimens are not acceptable), archival or fresh, collected after discontinuation of their most recent anticancer treatment and prior to the first administration of GEN1079. If an is unavailable, a procedure for obtaining a fresh tumor biopsy must be performed, provided it is performed according to standard of care and is deemed safe by the investigator.
  • Has acceptable laboratory test results prior to trial treatment administration, including count >150×10\^9/litre (L).

Parts 1 and 2:

  • Have histologically confirmed selected solid cancers that are or unresectable.
  • Prior protocol defined therapy is permitted, with no restrictions on the number of received or the time since the most recent therapy.

Part 3:

  • Have histologically confirmed selected solid cancer that is metastatic or unresectable.
  • Must have received a defined number of prior lines of a protocol defined regimen.

Key Exclusion Criteria:

  • Has intercurrent illness or known history of any of the following that could affect compliance with the protocol or interpretation of the results, including but not limited to:

    • diseases, eg, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), neuromyelitis optica (NMO), myasthenia gravis (MG), cold agglutinin disease (CAD), atypical hemolytic uremic syndrome (aHUS), immunoglobulin A (IgA) nephropathy, inflammatory bowel disease (IBD; Crohn's and ulcerative colitis).
    • Grade ≥3 allergic reactions to prior monoclonal antibody therapy.
    • Known history of interstitial lung disease (ILD) Grade ≥3 or prior or ongoing noninfectious pneumonitis with evidence of progressive fibrotic changes on baseline imaging, unless clinically and radiologically stable for ≥6 months with preserved pulmonary function (eg, diffusing capacity of the lungs for carbon monoxide [DLCO] ≥ 50% predicted).
    • Disorders associated with platelet function defects, decreased number of platelets (eg, splenomegaly, chronic liver disease or bleeding disorders such as hemophilia or Von Willebrand disease), or a known history or high risk of bleeding events requiring transfusions or hospitalizations.
  • Treatment with any plasma-based therapy within 7 days prior to Cycle 1 Day 1.
  • Any history of intracerebral arteriovenous malformation (shunts), cerebral aneurysm, spinal cord compression (from disease), carcinomatous meningitis, or stroke. Note: >1 month prior to screening is allowed.
  • Participants who, in the event of a medical complication during the trial treatment period, would be unable to temporarily discontinue and restart anticoagulant/antiplatelet therapy using appropriate bridging strategies (eg, low molecular weight heparin) in alignment with local standard of care.

Note: Other protocol-defined Inclusion and Exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
121 participants (estimated)

Study arms

  • Experimental
    Part 1: GEN1079 Dose Escalation

    Cohorts of participants will receive escalating doses of GEN1079 in up to 5 DLs.

    Drug: GEN1079

  • Experimental
    Part 2: GEN1079 Dose Refinement

    Cohorts of participants will receive up to 3 DLs of based on data from the Dose Escalation.

    Drug: GEN1079

  • Experimental
    Part 3: Expansion

    Cohorts of participants will receive up to 2 DLs of GEN1079 based on data from Dose Escalation/Dose Refinement.

    Drug: GEN1079

Interventions

  • DrugGEN1079

    Concentrate for solution.

06

What researchers measure

Primary outcomes

  1. Part 1 Dose Escalation: Number of Participants with Dose-limiting Toxicities (DLTs)

    Time frame: 21 days

  2. Part 1 Dose Escalation and Part 2 Dose Refinement: Number of Participants with Adverse Events (AEs)

    Time frame: Up to a maximum of approximately 67 weeks

  3. Part 3 Expansion: Objective Response Rate (ORR)

    Time frame: Up to a maximum of approximately 67 months

Secondary outcomes

  1. Part 1 Dose Escalation and Part 2 Dose Refinement: ORR

    Time frame: Up to a maximum of approximately 67 weeks

  2. Part 1 Dose Escalation and Part 2 Dose Refinement: Disease Control Rate (DCR)

    Time frame: Up to a maximum of approximately 67 weeks

  3. Part 1 Dose Escalation and Part 2 Dose Refinement: Duration Of Response (DOR)

    Time frame: Up to a maximum of approximately 67 weeks

  4. Part 1 Dose Escalation and Part 2 Dose Refinement: Time to Response (TTR)

    Time frame: Up to a maximum of approximately 67 weeks

  5. Part 1 Dose Escalation and Part 2 Dose Refinement: Maximum Concentration (Cmax) of GEN1079

    Time frame: Up to a maximum of approximately 12 weeks

  6. Part 1 Dose Escalation and Part 2 Dose Refinement: Time to Cmax (Tmax) of GEN1079

    Time frame: Up to a maximum of approximately 12 weeks

  7. Part 1 Dose Escalation and Part 2 Dose Refinement: Trough Concentration (Ctrough) of GEN1079

    Time frame: Up to a maximum of approximately 12 weeks

  8. Part 1 Dose Escalation and Part 2 Dose Refinement: Area Under the Concentration-time Curve from Time 0 to Last Quantifiable Sample (AUClast) of GEN1079

    Time frame: Up to a maximum of approximately 12 weeks

  9. Part 1 Dose Escalation and Part 2 Dose Refinement: Number of Participants with Anti-drug Antibodies (ADA) Against GEN1079

    Time frame: Up to a maximum of approximately 12 weeks

  10. Part 3 Expansion: DCR

    Time frame: Up to a maximum of approximately 67 weeks

  11. Part 3 Expansion: DOR

    Time frame: Up to a maximum of approximately 67 weeks

  12. Part 3 Expansion: TTR

    Time frame: Up to a maximum of approximately 67 weeks

  13. Part 3 Expansion: Number of Participants with AEs

    Time frame: Up to a maximum of approximately 67 weeks

  14. Part 3 Expansion: Cmax of GEN1079

    Time frame: Up to a maximum of approximately 12 weeks

  15. Part 3 Expansion: Tmax of GEN1079

    Time frame: Up to a maximum of approximately 12 weeks

  16. Part 3 Expansion: Ctrough of GEN1079

    Time frame: Up to a maximum of approximately 12 weeks

  17. Part 3 Expansion: AUClast of GEN1079

    Time frame: Up to a maximum of approximately 12 weeks

  18. Part 3 Expansion: Number of Participants with ADAs Against GEN1079

    Time frame: Up to a maximum of approximately 12 weeks

07

Study locations

12 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Jan 2031, 57 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2026
First posted
Feb 4, 2026
StartActual
Apr 7, 2026
Primary completionEst.
Jan 2031
CompletionEst.
Jan 2031
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07387068
Lead sponsor
Genmab
Responsible party
Sponsor
First posted
Feb 4, 2026
Start date
Apr 7, 2026
Primary completion
Jan 2031 (estimated)
Completion
Jan 2031 (estimated)
Last update
Sep 9, 2026

Study contacts

Genmab Trial Information
Contact
clinicaltrials@genmab.com
+4570202728
Study Official
study director · Genmab

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion